| A 26-week course of imatinib preserved β-cell function at 12 months in adults with recent-onset type 1 diabetes. Imatinib might offer a novel means to alter the course of type 1 diabetes (The Lancet Diabetes & Endocrinology)
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (NEJM)
Despite obesity specialists’ enthusiasm for the drug’s potential, they also described major barriers to uptake and accessibility. Those barriers, they say, are rooted in the sordid legacy of weight-loss drugs and outdated notions of obesity (JAMA)
We concluded that liraglutide improves cognitive decline in patients with type 2 diabetes mellitus (Journal of the American Academy of Heart Association)
The relationships between the magnitude of weight loss, improvement in glycemic control, and cardiorenal benefits with SGLT2i are still unclear (Diabetes Therapy)
As novel and stable glucagon formulations are being approved and launched on the market, new possibilities for improved hypoglycaemia rescues and new treatment approaches emerge (Diabetes/Metabolism Research and Reviews)
Late intensification of glucose-lowering therapy after first-line treatment failure reduces the likelihood of reaching recommended treatment goals (Diabetes Research and Clinical Practice)
| 
